Published in Gene Therapy Weekly, July 28th, 2005
Any remaining warrants relating to these financings have now expired. The company now has 42.1 million shares issued and outstanding with 47.2 million shares on a fully diluted basis.
"By exercising these warrants, our shareholders have demonstrated their confidence in our strategy for growth," said Jim Pelot, chief financial...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.